- Results from an observational, retrospective study suggest that ustekinumab is associated with superior drug survival rates compared with adalimumab and etanercept in children with psoriasis.
Why this matters
- Drug survival is an important factor affecting long-term performance in real-world settings.
- Age at initiation (P<.001 age at onset of psoriasis and baseline severity were associated with choice first-line agent.>
- Ustekinumab was associated with a higher drug survival rate compared with adalimumab and etanercept in the total cohort (P<.0001 style="list-style-type:circle;">
- P=.0003 for patients with plaque-type psoriasis
- P=.0007 for patients naive to biological agents
- 134 children with psoriasis who underwent 184 treatment courses (70 etanercept, 68 adalimumab, 46 ustekinumab) were included.
- Funding: None disclosed.
- Potential reporting bias.
- Retrospective study design.